Aflibercept AVE0005

DRUG4 trials

Sponsors

Sanofi

Conditions

Colorectal Cancer MetastaticNeoplasm Malignant

Phase 1

A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

CompletedNCT01930552

SanofiNeoplasm Malignant

Start: 2013-09-30End: 2014-12-31Updated: 2015-01-07

Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

TerminatedNCT01955629

SanofiColorectal Cancer Metastatic

Start: 2013-12-31End: 2015-03-31Updated: 2016-04-18

Phase 2

Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer

WithdrawnNCT02085005

SanofiColorectal Cancer Metastatic

Start: 2014-03-31End: 2016-08-31Updated: 2014-11-18

Phase 3

Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

CompletedNCT01571284

SanofiColorectal Cancer Metastatic

Start: 2012-05-30End: 2017-01-31Updated: 2018-04-17

Related Papers

Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).

2019-05-1514 citations

Aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Safety and quality of life (QoL) data from the Spanish subgroup of the Aflibercept Safety and Quality-of-Life Program (ASQoP).

Journal of Clinical Oncology2017-02-01

Ziv-aflibercept in combination with FOLFIRI for 2nd-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP/AFEQT) in patients age 65 and older.

Journal of Clinical Oncology2015-05-20

Ziv-aflibercept in combination with FOLFIRI for 2nd-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP/AFEQT) in patients pretreated with bevacizumab.

Journal of Clinical Oncology2015-05-20

Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program in pts pretreated with bevacizumab (B).

Journal of Clinical Oncology2015-01-203 citations

Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT) in patients age 65 or older.

Journal of Clinical Oncology2015-01-201 citations

Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program.

Journal of Clinical Oncology2014-05-201 citations

Ziv-aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: Third interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies).

Journal of Clinical Oncology2014-05-20

Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients ≥65.

Journal of Clinical Oncology2014-01-208 citations

Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).

Journal of Clinical Oncology2014-01-203 citations